Biotech Values

[DewDiligence]

ADXS—In general, I stay far and wide away from companies that have THAT many irons in the fire at such an early stage in their life.

That’s my general investing philosophy too, but I’ve made an exception with ADXS because: they are well-funded and reasonably disciplined in expense control (#msg-127726151); all of the programs are based on a shared technology platform; and there are partnerships with AMGN, AZN, and MRK to confer some validation for what ADXS is doing.